26 filings · most recent first
RVMD 8-K Filings
Revolution Medicines Announces Planned Retirement Of President And Key
Revolution Medicines Announces Positive Daraxonrasib Trial Results And Strong
Revolution Medicines Inc Issues 500 Million Convertible Senior Notes
Revolution Medicines Announces Major Equity Offering
Revolution Medicines Announces Positive Phase 3 Trial Results For Daraxonrasib
Revolution Medicines Announces 2025 Financial Results And Corporate Progress
Revolution Medicines Announces Third Quarter 2025 Financial Results And
Revolution Medicines Receives Fda Voucher For Daraxonrasib
Revolution Medicines Reports Positive Clinical Data For Daraxonrasib In
Revolution Medicines Announces Voting Results From Annual Meeting
Revolution Medicines Secures 2 Billion Funding Agreement With Royalty Pharma
Barbara Weber Md Resigns From Revolution Medicines Board
Revolution Medicines Completes Public Offering
Revolution Medicines Updates Clinical Trials For Rmc6236 And Rmc6291
Revolution Medicines Announces Preliminary Clinical Data For Rmc9805
Revolution Medicines Reports Updated Clinical Data For Rmc6236 In Pdac Patients
Revolution Medicines Updates On Financial Guidance And Clinical Progress For
Revolution Medicines Inc Announces Voting Results From 2024 Annual Meeting
Revolution Medicines Discloses Corporate Presentation And Pipeline Update
Revolution Medicines Announces Q2 2025 Financial Results And Progress
Revolution Medicines Announces Q1 2025 Financial Results And Corporate Updates
Revolution Medicines Reports Q4 2024 Financial Results And Clinical Progress
Revolution Medicines Announces Third Quarter 2024 Financial Results And
Revolution Medicines Announces Q2 2024 Financial Results And Appoints New
Revolution Medicines Reports Q1 2024 Financial Results And Corporate Update
Revolution Medicines Reports Q4 2023 Financial Results And Corporate Progress